---
title: "HCP Analysis using Mass Spectrometry: Strategies for Your Process Development Toolkit"
description: This webinar will benefit all scientists considering adding mass spectrometry to their host cell protein detection strategy.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019.png?width=700&name=New-ATE-Logo2019.png)

## HCP Analysis using Mass Spectrometry: Strategies for Your Process Development Toolkit

 Please join us for this free, live Ask the Expert webcast.

Just fill out the form below to register.

|  |
| --- |

## Presenters:

******![Christina Morris BPS](https://bpi.bioprocessintl.com/hs-fs/hubfs/Christina%20Morris%20BPS.jpg?width=150&name=Christina%20Morris%20BPS.jpg)******

**Dr. Christina Morris**

 Senior Scientist

BioPharmaSpec

 

Christina completed her BSc in Biology at Imperial College and went on to obtain her PhD in biomedical engineering in 2013. She worked on an artificial pancreas project for type 1 diabetes treatment and gained significant experience in hormone regulation for biologically inspired medical technologies. This included the development of mass-spectrometric techniques for the simultaneous measurement of glucagon and insulin from pancreatic tissue. At BioPharmaSpec, Christina focuses on physicochemical analyses and quantitative mass spectrometry, including the characterization of host cell proteins.

## About this event:

#### Date: March 18, 2021

#### Time: 11 am EST | 8 am PST | 4 pm CET

#### Duration: 15 minutes

Expression systems of either mammalian, yeast, or bacterial origin are commonly used as host cells for the production of biopharmaceuticals. As a consequence of using these systems, endogenous host cell proteins (HCPs) will inevitably copurify or will be coexpressed and contaminate the product material. It is a regulatory requirement to identify and monitor process-related impurities such as HCPs, and a qualitative and quantitative assessment of the components in the final drug product must be performed.

HCPs should be assessed early in product development to show that improvements in downstream purification through process development are having a positive impact on the levels of HCPs present, serving to ultimately improve the quality of the product. HCP-mass spectrometry (HCP-MS) analysis is an orthogonal approach to enzyme-linked immunosorbent assay (ELISA) and can be used to achieve greater coverage and knowledge of the HCP profile of a biopharmaceutical. The strategies and rationale for implementing HCP-MS analysis will differ depending on the product, process, and other project-specific variables.

This webinar will benefit all scientists considering adding MS to their HCP detection strategy by discussing topics including

- spectral library generation,
- sample selection for quantitative analysis, and
- MS data expectations, including advantages and limitations.

-  

-  

©2015 BioProcess International All Rights reserved